Published in J Virol on February 01, 2004
Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest (2009) 3.80
Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol (2004) 3.43
Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology (2008) 2.81
Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology (2009) 2.24
Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc Natl Acad Sci U S A (2008) 1.82
Coinfection with HIV-1 and HCV--a one-two punch. Gastroenterology (2009) 1.78
Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis (2012) 1.66
Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection. Nat Med (2013) 1.64
Immune responses to HCV and other hepatitis viruses. Immunity (2014) 1.52
The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design. Gut (2015) 1.51
Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J Virol (2008) 1.33
Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. J Infect Dis (2008) 1.30
Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology (2010) 1.28
Current progress in development of hepatitis C virus vaccines. Nat Med (2013) 1.28
Foxp3+CD4+CD25+ T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis C. Blood (2006) 1.25
Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection. J Hepatol (2011) 1.18
Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines (2009) 1.16
Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus. Gastroenterology (2012) 1.12
Delayed induction, not impaired recruitment, of specific CD8⁺ T cells causes the late onset of acute hepatitis C. Gastroenterology (2011) 1.09
The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res (2014) 1.07
Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus. J Virol (2008) 1.05
Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Vaccine (2008) 1.04
Strain-specific T-cell suppression and protective immunity in patients with chronic hepatitis C virus infection. J Virol (2005) 1.03
Will there be a vaccine to prevent HCV infection? Semin Liver Dis (2014) 1.02
The kinetics of hepatitis C virus-specific CD8 T-cell responses in the blood mirror those in the liver in acute hepatitis C virus infection. J Virol (2008) 0.98
Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with non-genotype 1 infection. Blood (2007) 0.98
Hepatitis C virus NS3/NS4A DNA vaccine induces multiepitope T cell responses in rhesus macaques mimicking human immune responses [corrected]. Mol Ther (2011) 0.98
Neutralizing antibodies in hepatitis C virus infection. World J Gastroenterol (2007) 0.95
The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design. J Infect Dis (2012) 0.95
Prospects for dendritic cell vaccination in persistent infection with hepatitis C virus. J Clin Virol (2004) 0.94
Protective immunity against hepatitis C: many shades of gray. Front Immunol (2014) 0.94
Candidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunities. Vaccine (2010) 0.91
Clinical implications of chemokines in acute and chronic hepatitis C virus infection. Yonsei Med J (2011) 0.89
Hepatitis C virus vaccines among people who inject drugs. Clin Infect Dis (2013) 0.87
Private aspects of heterologous immunity. J Exp Med (2005) 0.87
Immune control and failure in HCV infection--tipping the balance. J Leukoc Biol (2014) 0.87
Conserved peptides within the E2 region of Hepatitis C virus induce humoral and cellular responses in goats. Virol J (2009) 0.86
Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol (2016) 0.86
Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection-the InC3 Study. J Infect Dis (2015) 0.85
Hepatitis C virus quasispecies in HIV-infected women: role of injecting drug use and highly active antiretroviral therapy (HAART). Hepatology (2007) 0.83
Two distinct functional patterns of hepatitis C Virus (HCV)-specific T cell responses in seronegative, aviremic patients. PLoS One (2013) 0.82
Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-α Based Therapy. Mediators Inflamm (2015) 0.82
T cell responses in hepatitis C virus infection: historical overview and goals for future research. Antiviral Res (2014) 0.82
Codelivery of IL-7 Augments Multigenic HCV DNA Vaccine-induced Antibody as well as Broad T Cell Responses in Cynomolgus Monkeys. Immune Netw (2010) 0.82
Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genes. Virol J (2011) 0.81
Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future Perspectives. Viruses (2009) 0.80
Genotype-specific vs. cross-reactive host immunity against a macroparasite. PLoS One (2013) 0.80
Prospects for prophylactic hepatitis C vaccines based on virus-like particles. Hum Vaccin Immunother (2013) 0.78
Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees. World J Hepatol (2015) 0.78
Cross reactive cellular immune response to HCV genotype 1 and 4 antigens among genotype 4 exposed subjects. PLoS One (2014) 0.77
Innate and Adaptive Immune Responses in Chronic HCV infection. Curr Drug Targets (2015) 0.77
Vitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon-α and ribavirin. Int J Clin Exp Med (2015) 0.76
Immune protection against reinfection with nonprimate hepacivirus. Proc Natl Acad Sci U S A (2017) 0.75
Construction and Immunogenicity Analysis of Hepatitis C Virus (HCV) Truncated Non-Structural Protein 3 (NS3) Plasmid Vaccine. Jundishapur J Microbiol (2016) 0.75
Lessons from Nature: Understanding Immunity to HCV to Guide Vaccine Design. PLoS Pathog (2016) 0.75
Immunogenicity and functional characterization of Leishmania-derived hepatitis C virus envelope glycoprotein complex. Sci Rep (2016) 0.75
Adaptive immunity to hepatitis C virus. Viruses (2009) 0.75
Will there be a vaccine to protect against the hepatitis C virus? Gastroenterology (2012) 0.75
Hepatitis C cross-genotype immunity and implications for vaccine development. Sci Rep (2017) 0.75
Efficient initiation of HCV RNA replication in cell culture. Science (2000) 15.12
Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med (2000) 9.36
Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med (2001) 8.47
Analysis of a successful immune response against hepatitis C virus. Immunity (1999) 6.31
Effect of alpha interferon on the hepatitis C virus replicon. J Virol (2001) 6.18
Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis (2000) 6.05
Protection against persistence of hepatitis C. Lancet (2002) 5.94
Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A (2002) 5.81
The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science (2000) 5.49
Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A (2002) 5.28
Lack of protective immunity against reinfection with hepatitis C virus. Science (1992) 4.94
DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol (2001) 4.22
Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A (1994) 3.76
The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity (2001) 3.52
Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci U S A (1994) 3.34
Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci U S A (1995) 3.20
Genetic epidemiology of hepatitis C virus throughout egypt. J Infect Dis (2000) 3.01
Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis (2000) 2.98
Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology (2002) 2.53
Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. J Gen Virol (2001) 2.40
Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol (2002) 2.31
Immunity in hepatitis C infection. J Infect Dis (1992) 2.28
Determinant of HIV-1 mutational escape from cytotoxic T lymphocytes. J Exp Med (2003) 2.17
Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J Virol (1999) 1.98
Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology (2001) 1.94
Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol (2003) 1.93
Hepatocyte turnover during resolution of a transient hepadnaviral infection. Proc Natl Acad Sci U S A (2003) 1.58
Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by alpha, beta, and gamma interferons. J Virol (2002) 1.51
Hepatitis C and human immunodeficiency virus infection. Hepatology (2002) 1.44
Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J Virol (2001) 1.17
Advances in model systems for hepatitis C virus research. Virology (2002) 1.14
The chimpanzee model of hepatitis C virus infections. ILAR J (2001) 1.13
Viral escape and T cell exhaustion in hepatitis C virus infection analysed using Class I peptide tetramers. Immunol Lett (2003) 1.10
Clinical Medical Research Award. Hepatitis C virus and eliminating post-transfusion hepatitis. Nat Med (2000) 1.08
Clinical specificity and sensitivity of a blood screening assay for detection of HIV-1 and HCV RNA. Transfusion (2002) 0.92
Sensitivity of the Procleix HIV-1/HCV assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA in a high-risk population. J Clin Microbiol (2002) 0.87
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 11.62
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (2006) 10.18
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 8.22
Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A (2005) 6.64
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis (2004) 6.13
Protection against persistence of hepatitis C. Lancet (2002) 5.94
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet (2002) 5.60
Exceeding the limits of liver histology markers. J Hepatol (2008) 5.06
Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci U S A (2006) 4.54
Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol (2005) 3.93
Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78
Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol (2004) 3.43
Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis (2004) 3.30
Hepatitis C and progression of HIV disease. JAMA (2002) 3.15
Occult hepatitis B. Lancet Infect Dis (2002) 3.09
Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis (2005) 3.06
IL28B and the control of hepatitis C virus infection. Gastroenterology (2010) 3.02
In vivo imaging of glucose uptake and metabolism in tumors. Nat Med (2013) 3.01
Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology (2008) 3.00
Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 2.99
Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med (2005) 2.75
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (2002) 2.71
Genomic response to interferon-alpha in chimpanzees: implications of rapid downregulation for hepatitis C kinetics. Hepatology (2006) 2.69
Hepatitis C in the HIV-Infected Person. Ann Intern Med (2003) 2.67
Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol (2005) 2.64
Limited uptake of hepatitis C treatment among injection drug users. J Community Health (2008) 2.61
G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol (2005) 2.61
Needlestick transmission of hepatitis C. JAMA (2002) 2.55
Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology (2005) 2.52
Mechanism of induction and suppression of antiviral immunity directed by virus-derived small RNAs in Drosophila. Cell Host Microbe (2008) 2.48
SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology (2009) 2.45
Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS (2005) 2.34
Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology (2009) 2.24
Identification and quantification of antioxidant components of honeys from various floral sources. J Agric Food Chem (2002) 2.23
High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther (2011) 2.20
Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J Exp Med (2005) 2.16
Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology (2012) 2.14
GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology (2013) 2.14
Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis (2005) 2.02
Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States. J Infect Dis (2007) 1.96
Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1. J Infect Dis (2009) 1.93
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS (2007) 1.92
Hepatitis C virus infection and incident type 2 diabetes. Hepatology (2003) 1.89
Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology (2009) 1.89
Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA (2012) 1.88
Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol (2004) 1.85
Lack of response to exogenous interferon-alpha in the liver of chimpanzees chronically infected with hepatitis C virus. Hepatology (2007) 1.84
HLA-Cw*04 and hepatitis C virus persistence. J Virol (2002) 1.83
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS (2006) 1.82
Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis (2009) 1.80
Changes in blood-borne infection risk among injection drug users. J Infect Dis (2011) 1.74
Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J Virol (2010) 1.66
Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. J Virol (2008) 1.66
Peripheral blood count abnormalities among patients with hepatitis C in the United States. Hepatology (2002) 1.65
Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology (2006) 1.63
Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy. AIDS Res Hum Retroviruses (2007) 1.63
Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. J Urban Health (2004) 1.62
Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1. Mol Immunol (2008) 1.60
PTK7 as a novel marker for favorable gastric cancer patient survival. J Surg Oncol (2012) 1.60
ABCB11 gene mutations in Chinese children with progressive intrahepatic cholestasis and low gamma glutamyltransferase. Liver Int (2009) 1.60
Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1. J Virol (2006) 1.59
Hyperlactataemia syndromes associated with HIV therapy. Lancet Infect Dis (2003) 1.57
Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology (2010) 1.53
Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection. J Virol (2003) 1.52
A sensitive genotyping assay for detection of drug resistance mutations in reverse transcriptase of HIV-1 subtypes B and C in samples stored as dried blood spots or frozen RNA extracts. J Virol Methods (2006) 1.49
Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS (2004) 1.44
Serum albumin as a prognostic indicator for HIV disease progression. AIDS Res Hum Retroviruses (2006) 1.42